Barclays Q2 Profit Beats Forecasts as Investment Banking Strength Offsets Higher Costs 
Tech Stock Positioning Nears Neutral as Investor Rotation Enters Final Phase, Deutsche Bank Says 
CXMT IPO Debut in Shanghai Puts $85.5 Billion Chipmaker in Spotlight 
Do investment tax breaks work? A new study finds the evidence is ‘mixed at best’ 
U.S. Stock Futures Rise as Trump Takes Office, Corporate Earnings Awaited 
Zabka Shares Drop 10% as Seven & i Abandons Investment Plans 
China's Refining Industry Faces Major Shakeup Amid Challenges 
Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth 
Nvidia Eyes $250B Guarantee for OpenAI’s Massive Ohio AI Data Center Project 
Why the Middle East is being left behind by global climate finance plans 
Why your retirement fund might soon include cryptocurrency 
ASML, Applied Materials Slide as China DUV Chip Equipment Breakthrough Sparks Market Jitters 
Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns 
Insignia Financial Shares Hit 3-Year High Amid Bain and CC Capital Bidding War 
U.S. Condemns China's Dominance in Global Shipbuilding and Maritime Sectors 
Tech Stocks Rally in Asia-Pacific as Dollar Remains Resilient 
Bitcoin Hits $100K Milestone Amid Optimism Over Trump Policies 
Samsung Biologics would invest 1.74 trillion in building a massive fourth plant in Songdo, Incheon, that would employ 1,800 new employees by 2023 and produce 256,000 liters of drug substances in a single generation.
According to CEO Kim Tae-han, the construction will increase its output at its Songdo complex 1 to 620,000 liters, accounting for 30 percent of the world’s contract manufacturing market.
Samsung Biologics currently has a combined 364,000-liter capacity at its three existing plants, with one of those producing 180,000 liters and touted as having the world’s largest single-plant capacity.
Construction of the fourth plant will take 36 months and poised to create 27,000 jobs and bring in 5.6 trillion won in economic benefits.
Plant 4 will be a hybrid that has both stainless steel and single-use disposable bioreactors.
With speed being of critical significance in the biologics market, the new plant will be a game-changer.
It would provide a one-stop service comprising of cell line development and the manufacturing of clinical samples, active pharmaceutical ingredients, drug substances, and fill-and-finish drug products.
The one-stop service would dramatically reduce the time spent on commercializing a drug.
